950842-31-6Relevant articles and documents
In vitro and in vivo isotope effects with hepatitis C protease inhibitors: Enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats
Maltais, Fran?ois,Jung, Young Chun,Chen, Minzhang,Tanoury, Jerry,Perni, Robert B.,Mani, Nagraj,Laitinen, Leena,Huang, Hui,Liao, Shengkai,Gao, Hongying,Tsao, Hong,Block, Eric,Ma, Chien,Shawgo, Rebecca S.,Town, Christopher,Brummel, Christopher L.,Howe, David,Pazhanisamy,Raybuck, Scott,Namchuk, Mark,Bennani, Youssef L.
, p. 7993 - 8001 (2009)
Telaprevir 2 (VX-950), an inhibitor of the hepatitis C virus (HCV a) NS3-4A protease, is in phase 3 clinical trials. One of the major metabolites of 2 is its P1-(R)-diastereoisomer, 3 (VRT-394), containing an inversion at the chiral center next